LINKSchering-Plough Corp. received approval from the Food and Drug Administration to market Temodar as a brain-cancer treatment in adults. In a press release Wednesday, the drug company, which produces temozolomide under the Temodar brand, said capsules of the drug are approved for use along with radiotherapy to treat adults who were recently diagnosed with glioblastoma multiforme, a form of malignant brain cancer. Temodar may then be used for maintenance.

Schering-Plough also received final approval for the drug as a treatment for adult patients with refractory anaplastic astrocytoma, or AA, which is another form of brain tumor.

MOREAccording to a recent article published in the Journal of the American Medical Association, treatment for gliomas varies widely in the United States, with many patients not receiving chemotherapy as part of their treatment regimen.

LINKAccording to a recent article published in the journal Cancer, healthcare providers greatly underestimate the incidence of delayed chemotherapy-induced nausea and vomiting in patients undergoing treatment for cancer. However, delayed chemotherapy-induced nausea and vomiting may be reduced or alleviated with preventive use of newer anti-emetic agents such as Aloxi®.

LINK: "Case Studies"